{
    "clinical_study": {
        "@rank": "51881", 
        "arm_group": [
            {
                "arm_group_label": "group 1", 
                "arm_group_type": "Experimental", 
                "description": "Group 1 will be administered with Clopidogrel 75mg daily until the end of the trial"
            }, 
            {
                "arm_group_label": "group 2", 
                "arm_group_type": "Experimental", 
                "description": "Group 2 will be administered with Clopidogrel 150mg daily until the end of trial"
            }, 
            {
                "arm_group_label": "group 3", 
                "arm_group_type": "Experimental", 
                "description": "Group 3 will be administered with Ticagrelor 90mg twice daily until the end of the trial"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to compare the efficacy and safety of ticagrelor   with\n      clopidogrel"
        }, 
        "brief_title": "Efficacy and Safety Study of Ticagrelor", 
        "completion_date": {
            "#text": "July 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Acute Coronary Syndrome", 
        "condition_browse": {
            "mesh_term": "Acute Coronary Syndrome"
        }, 
        "detailed_description": {
            "textblock": "180 elective percutaneous coronary intervention patients with clopidogrel resistance were\n      randomized to three groups, Group 1:received clopidogrel 75mg qd ;Group 2:received\n      clopidogrel 150mg qd ; Group 3:received ticagrelor 90mg bid after PCI.Platelet funtion were\n      tested by flowcytometric vasodilator-stimulated phosphoprotein(VASP) analysis before PCI,and\n      3days,7days and 1 month after PCI,respectively.The aim of our study is to compare the\n      efficacy and safety of ticagrelor   with clopidogrel"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  1.Clinical diagnosis of ACS 2.undergoing PCI 3.with clopidogrel resistance\n\n        Exclusion Criteria:\n\n          -  1.any contraindication against the use of clopidogrel and ticagrel 2.Contradiction to\n             aspirin and contrast medium 3.Life expectancy less than 1 year 4.Tumor or\n             inflammatory diseases5. fibrinolytic therapy within 24 hours before randomization 6.a\n             need  for oral  anticoagulation therapy 7. an  increased  risk  of  bradycardia\n             8.concomitant  therapy with  a  strong  cytochrome P-450 3A inhibitor or inducer 9.a\n             history of asthma."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "180", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 14, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01812330", 
            "org_study_id": "20130118 CR"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "group 1", 
                    "group 2"
                ], 
                "intervention_name": "Clopidogrel", 
                "intervention_type": "Drug", 
                "other_name": "Plavix"
            }, 
            {
                "arm_group_label": "group 3", 
                "intervention_name": "Ticagrelor", 
                "intervention_type": "Drug", 
                "other_name": "Brilique"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Clopidogrel", 
                "Ticagrelor"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "ACS", 
            "CR", 
            "PCI", 
            "Platelet funtion", 
            "Ticagrelor"
        ], 
        "lastchanged_date": "February 20, 2014", 
        "location": {
            "contact": {
                "email": "lhl518@vip.sina.com", 
                "last_name": "huiliang liu, doctor", 
                "phone": "86-10-57976531"
            }, 
            "contact_backup": {
                "last_name": "yujie wei, doctor", 
                "phone": "86-10-57976707"
            }, 
            "facility": {
                "address": {
                    "city": "Beijing", 
                    "country": "China", 
                    "zip": "100039"
                }, 
                "name": "General Hospital of Chinese People's Armed Police Forces"
            }, 
            "investigator": {
                "last_name": "yingping xiao, doctor", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "3", 
        "official_title": "The Effect of Ticagrelor on Acute Coronary Syndrome Patients With Clopidogrel Resistance Undergoing Percutaneous Coronary Intervention", 
        "overall_contact": {
            "email": "lhl518@vip.sina.com", 
            "last_name": "huiliang liu, doctor", 
            "phone": "86-10-57976531"
        }, 
        "overall_contact_backup": {
            "last_name": "yujie wei, doctor", 
            "phone": "86-10-57976707"
        }, 
        "overall_official": {
            "affiliation": "Department of Cardiology of General Hospital of Chinese People's Armed Police Forces", 
            "last_name": "huiliang liu, doctor", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Platelet funtion were tested by flowcytometric vasodilator-stimulated phosphoprotein(VASP) analysis.And a platelet reactivity index (PRI) was calculated.", 
            "measure": "PRI", 
            "safety_issue": "Yes", 
            "time_frame": "post operative 1 month"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01812330"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "results_reference": [
            {
                "PMID": "20194878", 
                "citation": "Gurbel PA, Bliden KP, Butler K, Antonino MJ, Wei C, Teng R, Rasmussen L, Storey RF, Nielsen T, Eikelboom JW, Sabe-Affaki G, Husted S, Kereiakes DJ, Henderson D, Patel DV, Tantry US. Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study. Circulation. 2010 Mar 16;121(10):1188-99. doi: 10.1161/CIRCULATIONAHA.109.919456. Epub 2010 Mar 1."
            }, 
            {
                "PMID": "19761935", 
                "citation": "Cuisset T, Frere C, Quilici J, Poyet R, Gaborit B, Bali L, Brissy O, Morange PE, Alessi MC, Bonnet JL. Comparison of omeprazole and pantoprazole influence on a high 150-mg clopidogrel maintenance dose the PACA (Proton Pump Inhibitors And Clopidogrel Association) prospective randomized study. J Am Coll Cardiol. 2009 Sep 22;54(13):1149-53. doi: 10.1016/j.jacc.2009.05.050."
            }, 
            {
                "PMID": "15738352", 
                "citation": "Gurbel PA, Bliden KP, Zaman KA, Yoho JA, Hayes KM, Tantry US. Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study. Circulation. 2005 Mar 8;111(9):1153-9. Epub 2005 Feb 28."
            }, 
            {
                "PMID": "16260639", 
                "citation": "von Beckerath N, Taubert D, Pogatsa-Murray G, Sch\u00f6mig E, Kastrati A, Sch\u00f6mig A. Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial. Circulation. 2005 Nov 8;112(19):2946-50. Epub 2005 Oct 31."
            }, 
            {
                "PMID": "19717846", 
                "citation": "Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA; PLATO Investigators; Freij A, Thors\u00e9n M. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009 Sep 10;361(11):1045-57. Epub 2009 Aug 30."
            }, 
            {
                "PMID": "19324253", 
                "citation": "Jeong YH, Lee SW, Choi BR, Kim IS, Seo MK, Kwak CH, Hwang JY, Park SW. Randomized comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity: results of the ACCEL-RESISTANCE (Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With Clopidogrel Resistance) randomized study. J Am Coll Cardiol. 2009 Mar 31;53(13):1101-9."
            }
        ], 
        "secondary_outcome": [
            {
                "description": "cardiovascular death,angiographically con\ufb01rmed stent thrombosis, recurrent acute coronary syndrome de\ufb01ned by the American College of Cardiology/American Heart Association guidelines,and recurrent revascularization by either coronary angioplasty or bypass surgery", 
                "measure": "Major adverse cardiac events(MACEs)", 
                "safety_issue": "Yes", 
                "time_frame": "follow-up for 1 month"
            }, 
            {
                "description": "Major bleeding was de\ufb01ned as intracranial bleeding or clinically-overt bleeding associated with a decrease in hemoglobin of 50 g/L, according to the Thrombolysis inMyocardial Infarction (TIMI) criteria .Minor bleeding was also de\ufb01ned according to TIMI criteria .", 
                "measure": "major and minor bleeding", 
                "safety_issue": "Yes", 
                "time_frame": "follow-up for 1 month"
            }
        ], 
        "source": "General Hospital of Chinese Armed Police Forces", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "General Hospital of Chinese Armed Police Forces", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2013"
    }
}